Simvastatin Tablets Recalled Due to Manufacturing Process Deviations
Preferred Pharmaceuticals is recalling Simvastatin Tablets, USP, 20 mg, in three package sizes due to manufacturing process deviations at Accord Healthcare. The affected tablets were distributed nationwide.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall with no reported illnesses, injuries, or hospitalizations. The hazard is manufacturing process deviations without a specific identified defect or confirmed harm, making it a precautionary recall rather than a severe or critical event.
Plain-English summary
Preferred Pharmaceuticals, Inc. is recalling Simvastatin Tablets, USP, 20 mg across three package sizes (30-count, 60-count, and 90-count bottles) due to manufacturing process deviations identified during a U.S. Food and Drug Administration inspection of Accord Healthcare, Inc.
The recalled tablets were distributed nationwide. Specific lot numbers and expiration dates are provided in the official FDA recall notice.
Consumers who have affected medication should contact their healthcare provider or pharmacy. Lot numbers can be checked against the official FDA recall information to determine if a specific product is affected.
The recalled product
- Product
- Simvastatin Tablets, USP, 20 mg, Packaged as: a) 90-count bottle (NDC 68788-9869-9); b) 60-count bottle (NDC 68788-9869-6); c) 30-count bottle (NDC 68788-9869-3), Rx only, Manufactured for: Accord Healthcare, lnc., Durham, NC 27703.
- Manufacturer
- Preferred Pharmaceuticals, Inc.
- Category
- Drug
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- a) Lot: A0923R
- Exp. Date: 2/28/2025
- A1222K
- B1822C
- Exp. Date: 5/31/2024
- C3022D
- F2322V
- Exp. Date: 6/30/2024
- H1522H
- Exp. Date: 8/31/2024
- I1621O
- Exp. Date: 1/31/2024
- I2222G
- J1822R
- Exp. Date: 9/30/2024
- L1621N
- b) Lot: F0822Q
- I0122J
- L0821C
- c) Lot: I1521P
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 17 recalled by Preferred Pharmaceuticals, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 17 products in this recall →Related recalls
Same manufacturer · Preferred Pharmaceuticals, Inc.
See all →- ModeratePreferred Pharmaceuticals Recalls Lidocaine Ointment Due to Content Uniformity Failures
FDA (Drugs) · 2026-10-14
- HighGeri-Care artificial tears lubricant eye drops recalled over sterility assurance
FDA (Drugs) · 2026-04-15
- ModerateOndansetron blister packs recalled because tablets are falling out
FDA (Drugs) · 2025-12-24
- ModerateClindamycin Hydrochloride Capsules Recalled for cGMP Deviations
FDA (Drugs) · 2025-05-07
- HighIbuprofen Tablets Recalled Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2024-09-04
Same hazard · manufacturing deviation
See all →- HighBaxter Recalls Vancomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- ModerateSynjardy XR Tablets Recalled Due to Manufacturing Deviations
FDA (Drugs) · 2026-07-08
- ModerateDuloxetine delayed-release capsules recalled for N-nitroso impurity contamination
FDA (Drugs) · 2026-05-13
- ModerateFentanyl Citrate Injectable Solution Recalled for cGMP Deviations
FDA (Drugs) · 2026-05-06
Similar recalls
- HighPrescription Drug Simvastatin Recalled for Manufacturing Deviations
FDA (Drugs) · 2023-03-08
- ModerateSimvastatin 20mg Tablets Recalled for Manufacturing Practice Deviations
FDA (Drugs) · 2023-04-05
- ModerateSimvastatin tablets recalled due to manufacturing process deviations
FDA (Drugs) · 2023-03-08
- HighSimvastatin 40 mg tablets recalled for manufacturing practice deviations
FDA (Drugs) · 2023-03-08
- ModerateDrug Manufacturer Recalls Simvastatin Tablets for Manufacturing Deviations
FDA (Drugs) · 2023-04-05
- ModerateSimvastatin Tablets Recalled Due to Manufacturing Practice Deviations
FDA (Drugs) · 2023-03-08